{
    "clinical_study": {
        "@rank": "94166", 
        "arm_group": {
            "arm_group_label": "Eliquis on Nonvalvular Atrial Fibrilliation patients", 
            "description": "Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study"
        }, 
        "brief_summary": {
            "textblock": "The primary objectives of this study are:\n\n        -  To estimate the incidence rate of unexpected adverse events\n\n        -  To characterize the bleeding events and assess risk factors of bleeding\n\n        -  To identify ancillary baseline variables that may also be associated with adverse\n           outcomes"
        }, 
        "brief_title": "Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "NonValvular Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are beginning to receive the treatment with this product under the\n             approved indications, dosage, and administration will be included in this study\n\n        Exclusion Criteria:\n\n          -  Patients who are receiving Eliquis outside of its approved indication will be\n             excluded from this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "University hospitals, general hospitals, and clinics that have relevant departments, such\n        as cardiology, cerebrovascular medicine, neurology, internal medicine, neurosurgery, etc,\n        where the surveillance drug is mainly prescribed"
            }
        }, 
        "enrollment": {
            "#text": "5500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007655", 
            "org_study_id": "CV185-286"
        }, 
        "intervention": {
            "arm_group_label": "Eliquis on Nonvalvular Atrial Fibrilliation patients", 
            "intervention_name": "Eliquis", 
            "intervention_type": "Drug", 
            "other_name": [
                "Apixaban", 
                "BMS-562247"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Cardiovascular", 
        "lastchanged_date": "December 10, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Site 0001"
            }, 
            "facility": {
                "address": {
                    "city": "Toyama", 
                    "country": "Japan", 
                    "zip": "930-8555"
                }, 
                "name": "Local Institution"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For Site information please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence rate of unexpected adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (At Eliquis initiation)"
            }, 
            {
                "measure": "Incidence rate of unexpected adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks after initiation"
            }, 
            {
                "measure": "Incidence rate of unexpected adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks after initiation"
            }, 
            {
                "measure": "Incidence rate of unexpected adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "104 week (discontinuation)"
            }, 
            {
                "measure": "Bleeding events and risk factors of bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (At Eliquis initiation)"
            }, 
            {
                "measure": "Bleeding events and risk factors of bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks after initiation"
            }, 
            {
                "measure": "Bleeding events and risk factors of bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks after initiation"
            }, 
            {
                "measure": "Bleeding events and risk factors of bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "104 week (discontinuation)"
            }, 
            {
                "measure": "Ancillary baseline variables that may also be associated with adverse outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (At Eliquis initiation)"
            }, 
            {
                "measure": "Ancillary baseline variables that may also be associated with adverse outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks after initiation"
            }, 
            {
                "measure": "Ancillary baseline variables that may also be associated with adverse outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks after initiation"
            }, 
            {
                "measure": "Ancillary baseline variables that may also be associated with adverse outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "104 week (discontinuation)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007655"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}